Elham Khodaverdi

Prof. Dr. Elham Khodaverdi

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SSSamaneh Sepahi
Samaneh Sepahi
SMSeyed Ahmad Mohajeri
Seyed Ahmad Mohajeri
SHSeyedeh Maryam Hosseini
Seyedeh Maryam Hosseini
EKElham Khodaverdi
Elham Khodaverdi
NSNasser Shoeibi
Nasser Shoeibi
STSayyed Abolghasem Sajadi Tabassi
Sayyed Abolghasem Sajadi Tabassi

1 March 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
HKHossein Kamali
Hossein Kamali
EKElham Khodaverdi
Elham Khodaverdi
FHFarzin Hadizadeh
Farzin Hadizadeh
SMSeyed Ahmad Mohajeri
Seyed Ahmad Mohajeri

1 January 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HKHossein Kamali
Hossein Kamali
MKMalihe Karimi
Malihe Karimi
MAMohammadreza Abbaspour
Mohammadreza Abbaspour
ANAzadeh Nadim
Azadeh Nadim
FHFarzin Hadizadeh
Farzin Hadizadeh
FEFarhad Eisvand
Farhad Eisvand

26 November 2018 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
EKElham Khodaverdi
Elham Khodaverdi
SMSepehr Maftouhian
Sepehr Maftouhian
AAAli Aliabadi
Ali Aliabadi
MHMohammad Hassanzadeh-Khayyat
Mohammad Hassanzadeh-Khayyat
FMFatemeh Mohammadpour
Fatemeh Mohammadpour
FHFarzin Hadizadeh
Farzin Hadizadeh

24 January 2014 in Journal of Sol-Gel Science and Technology
Verified
Journal Article
Closed access
PDF file
STSayyed A. Sajadi Tabassi
Sayyed A. Sajadi Tabassi
FTFarnaz Sadat Mirzazadeh Tekie
Farnaz Sadat Mirzazadeh Tekie
FHFarzin Hadizadeh
Farzin Hadizadeh
RRRahof Rashid
Rahof Rashid
EKElham Khodaverdi
Elham Khodaverdi
SMSeyed Ahmad Mohajeri
Seyed Ahmad Mohajeri

13 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SSSeyedeh Nesa Rezaeian Shiadeh
Seyedeh Nesa Rezaeian Shiadeh
FHFarzin Hadizadeh
Farzin Hadizadeh
EKElham Khodaverdi
Elham Khodaverdi
MVMahmoud Gorji Valokola
Mahmoud Gorji Valokola
SRSaleh Rakhshani
Saleh Rakhshani
Ali NokhodchiAli Nokhodchi
Ali Nokhodchi
In the current research, novel drug delivery systems based on in situ forming gel (ISFG) (PLGA-PEG-PLGA) and in situ forming implant (ISFI) (PLGA) were developed for one-month risperidone delivery. In vitro release evaluation, pharmacokinetics, and histopathology studies of ISFI, ISFG, and Risperdal CONSTA® were compared in rabbits. Formulation containing 50% (w/w %) of PLGA-PEG-PLGA triblock revealed sustained release for about one month. Scanning electron microscopy (SEM) showed a porous structure for ISFI, while a structure with fewer pores was observed in the triblock. Cell viability in ISFG formulation in the first days was more than ISFI due to the gradual release of NMP to the release medium. Pharmacokinetic data displayed that optimal PLGA-PEG-PLGA creates a consistent serum level in vitro and in vivo through 30 days, and histopathology results revealed nearly slight to moderate pathological signs in the rabbit’s organs. The shelf life of the accelerated stability test didn’t affect the results of the release rate test and demonstrated stability in 24 months. This research confirms the better potential of the ISFG system compared with ISFI and Risperdal CONSTA®, which would increase patients’ compliance and avoid problems of further oral therapy.